---
layout: post
title: "Advancing Drug Development for the Prevention of Spontaneous Preterm Birth; Public Meeting"
date: 2026-02-05 18:57:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-25816
original_published: 2023-11-22 00:00:00 +0000
significance: 8.00
---

# Advancing Drug Development for the Prevention of Spontaneous Preterm Birth; Public Meeting

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** November 22, 2023 00:00 UTC
**Document Number:** 2023-25816

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Advancing Drug Development for the Prevention of Spontaneous Preterm Birth." The meeting will be convened by Duke University's Robert J. Margolis, MD, Center for Health Policy (Duke-Margolis) and supported by a cooperative agreement with FDA. The meeting is intended to gather industry, family, clinician, researcher, ethicist, professional society, and other stakeholder input on the impact of preterm birth on families and on society, as well as on the ethical, regulatory, and clinical trial considerations surrounding the drug development for the prevention of spontaneous preterm birth.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/11/22/2023-25816/advancing-drug-development-for-the-prevention-of-spontaneous-preterm-birth-public-meeting)
- API: https://www.federalregister.gov/api/v1/documents/2023-25816

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
